Truist notes Alnylam (ALNY) shared “positive” topline data from the HELIOS-B study of Vutrisiran in ATTR amyloidosis with cardiomyopathy, or ATTR-CM, which the firm says is also a positive for Intellia Therapeutics’ (NTLA) NTLA-2001 for the same indication of ATTR given 2001’s similarly deep TTR reduction without the peaks and troughs of repeat siRNA injections, The firm, which believes Intellia’s NTLA-2001’s profile should “lead to superior clinical results,” keeps a Buy rating and $120 price target on Intellia shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics to present data from patients redosed with NTLA-2001
- Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
- Intellia Therapeutics Welcomes Brian Goff to Board of Directors
- Intellia Therapeutics Names Brian Goff to its Board of Directors
- Intellia Therapeutics appoints Brian Goff to board of directors